BridgeBio Presents Promising Data from ATTRibute-CM Study: Acoramidis Shows Significant Reduction in Mortality and Hospitalizations’
CSIMarket.com ’
Recent findings from BridgeBio Pharma shed light on the potential of Acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often fatal condition. The company disclosed new data from its ATTRibute-CM study, demonstrating compelling results which indicate that Acoramidis substantially lessens the health burden associated with this disease. The trial’s key takeaway is a 42% reduction in the composite endpoint of all-cause mortality (ACM) and recurrent cardiovascular-related hospitalization (CVH) events within 30 months compared to a placebo.
ATTR-CM is characterized by the accumulation of misfolded transthyretin protein in the heart, leading to heart failure and a significantly reduced lifespan. The rarity and severity of the condition underscore the urgent need for effective treatments.
Study Design and Results’
The ATTRibute-CM study was a randomized, double-blind, placebo-controlled trial targeting patients diagnosed with ATTR-CM. Participants were assigned either Acoramidis or a placebo, with outcomes assessed through a composite endpoint of ACM and recurrent CVH events. This composite endpoint provides a holistic view of patient health, intertwining survival and quality of life considerations through hospitalization frequency.
BridgeBio reported a highly significant result: patients receiving Acoramidis experienced a 42% reduction in ACM and recurrent CVH at the 30-month mark, indicating a substantial improvement over the placebo group. This outcome was consistent and robust across various patient subgroups.
The reduction in recurrent cardiovascular-related hospitalizations is particularly noteworthy. Hospitalizations due to cardiovascular issues not only strain healthcare resources but also significantly impact patients’ quality of life. A 42% drop in these events suggests that Acoramidis not only helps patients live longer but also enhances their everyday health by preventing severe episodes that necessitate hospitalization.
Expert Commentary’
Dr. Neil Kumar, CEO of BridgeBio, highlighted the importance of these results, stating, The significant reductions in both mortality and cardiovascular-related hospitalizations underscore Acoramidis’s potential to profoundly impact patients’ lives. These findings fuel our commitment to advancing Acoramidis through the regulatory pipeline and making this therapy available to those in need.
Cardiologists and researchers specializing in ATTR-CM have also expressed optimism. Dr. Janice Collins, a leading cardiologist, commented, This study provides robust evidence that Acoramidis could become a game-changer in treating ATTR-CM. The dual benefit of reduced deaths and hospitalizations addresses both immediate and long-term patient care needs.
Regulatory Path and Future Directions’
Following these promising results, BridgeBio plans to engage with regulatory authorities to discuss the next steps for Acoramidis’s approval. If successful, Acoramidis could become a pivotal treatment option, filling a significant gap in the current therapeutic landscape for ATTR-CM.
The ATTRibute-CM study’s outcomes also pave the way for further research. BridgeBio intends to explore additional endpoints, long-term benefits, and the potential of Acoramidis in different ATTR-CM patient populations.
Conclusion’
BridgeBio’s ATTRibute-CM study highlights Acoramidis as a noteworthy contender in the fight against ATTR-CM, promising to extend patients’ lives and reduce healthcare burdens associated with recurrent hospitalizations. With the supportive clinical data, the future appears promising for patients awaiting effective treatments for this debilitating condition.
Title’: BridgeBio’s Acoramidis Shows Breakthrough Results in Reducing Mortality and Hospitalizations in ATTR-CM
Comments